https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2018-04-01 / JAMA Oncol 2018 Apr;4(4):483-492
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2018-04-01 / JAMA Oncol 2018 Apr;4(4):483-4922018-04-01 00:00:002019-02-15 09:37:56Effect of Neoadjuvant Chemotherapy Plus Regional Hyperthermia on Long-term Outcomes Among Patients With Localized High-Risk Soft Tissue Sarcoma: The EORTC 62961-ESHO 95 Randomized Clinical Trial
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2018-03-30 / Oncotarget 2018 Mar;9(24):17014-17027
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2018-03-30 / Oncotarget 2018 Mar;9(24):17014-170272018-03-30 00:00:002019-02-15 08:49:53Molecular signatures associated with tumor-specific immune response in melanoma patients treated with dendritic cell-based immunotherapy
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2018-03-29 / Cancer Immunol Immunother 2018 Dec;67(12):1897-1910
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2018-03-29 / Cancer Immunol Immunother 2018 Dec;67(12):1897-19102018-03-29 00:00:002024-11-03 11:46:45Tumor lysate-based vaccines: on the road to immunotherapy for gallbladder cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2018-03-26 / J Immunol Res 2018;2018:8740976
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2018-03-26 / J Immunol Res 2018;2018:87409762018-03-26 00:00:002018-03-26 00:00:00Immunotherapy for Hepatocellular Carcinoma: Current Advances and Future Expectations
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2018-03-26 / Oncoimmunology 2018;7(7):e1445457
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2018-03-26 / Oncoimmunology 2018;7(7):e14454572018-03-26 00:00:002018-03-26 00:00:00Optimized dendritic cell vaccination induces potent CD8 T cell responses and anti-tumor effects in transgenic mouse melanoma models
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2018-03-21 / Semin. Cell Dev. Biol. 2019 Feb;86:77-88
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2018-03-21 / Semin. Cell Dev. Biol. 2019 Feb;86:77-882018-03-21 00:00:002019-03-25 10:43:23Dendritic cells as cancer therapeutics
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2018-03-18 / J Immunol Res 2018;2018:3982942
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2018-03-18 / J Immunol Res 2018;2018:39829422018-03-18 00:00:002019-02-15 08:49:53Proteomic Identification of Heat Shock-Induced Danger Signals in a Melanoma Cell Lysate Used in Dendritic Cell-Based Cancer Immunotherapy
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2018-03-08 / Exp Ther Med 2018 May;15(5):4522-4530
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2018-03-08 / Exp Ther Med 2018 May;15(5):4522-45302018-03-08 00:00:002019-02-15 09:00:23Overexpression of p53 delivered using recombinant NDV induces apoptosis in glioma cells by regulating the apoptotic signaling pathway
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2018-03-06 / J Immunother Cancer 2018 Mar;6(1):19
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2018-03-06 / J Immunother Cancer 2018 Mar;6(1):192018-03-06 00:00:002019-02-15 08:49:55Randomized phase II trial of autologous dendritic cell vaccines versus autologous tumor cell vaccines in metastatic melanoma: 5-year follow up and additional analyses
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2018-03-05 / J. Clin. Invest. 2018 Apr;128(4):1413-1428
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2018-03-05 / J. Clin. Invest. 2018 Apr;128(4):1413-14282018-03-05 00:00:002019-02-15 08:36:17PD-L1 in tumor microenvironment mediates resistance to oncolytic immunotherapy
